TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Boundless Bio Stock

Boundless Bio Stock

boundlessbio.comHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $252.05MM

Boundless Bio, founded in 2018, is a biopharmaceutical company that develops novel cancer therapeutics seeking to understand and treat intractable cancers. Boundless Bio aims to interrogate extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers. Boundless Bio is headquartered in La Jolla, California.

Learn more about Boundless Bio IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Boundless Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Boundless Bio’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Boundless Bio.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Boundless Bio investors also invested in these private companies

Wellington Management
Ra Capital Management
Arch Venture Partners
Fidelity Management & Research
Redmile Group
Logos Capital
Cambridge Innovation Capital
Leaps by Bayer
Sectoral Asset Management
HealthCap
Boxer Capital
Nextech Invest
National Cancer Institute
Surveyor Capital
Vertex Ventures HC
City Hill Ventures
Tavistock Group
PFM Health Sciences
GT Healthcare Capital Partners
Citadel Enterprise Americas

Team

Management Team

Zachary Hornby
Chief Executive Officer & President
Christian Hassig Ph.D
Chief Scientific Officer
Neil Abdollahian
Chief Business Officer
Jonathan Lim MD
Co-Founder
Benjamin Cravatt Ph.D
Co-Founder
Klaus Wagner Ph.D
Chief Medical Officer

Board Members

Christine Brennan Ph.D
Vertex Ventures HC
Fabio Pucci Ph.D
RA Capital Management
Kristina Burow
ARCH Venture Partners

Other companies like Boundless Bio in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Precision Neuroscience

Sector
Healthcare / BioTech & Pharma
 
 

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

BioAge

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$439.94MM

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Life Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$500MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

FIERCE BIOTECH 05/16/2023
Boundless ups fundraising by Leaps and bounds, adding another $100M haul
Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management.
BUSINESS WIRE 05/09/2023
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification
Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancer, today announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614).

Trending Companies

Frequently Asked Questions

Updated on: Apr 19, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.